Continuing trastuzumab after cancer progression extends survival

摘要

Continuing treatment with trastuzumab (Herceptin) increases progression-free survival in women with advanced HER2-positive breast cancer and whose cancer has progressed despite use of the drug, results from the first randomised study to assess this issue show. The GBG-26 study randomised 156 women with HER2-positive locally advanced or metastatic breast cancer who had previously been treated with first-line trastuzumab, with or without chemotherapy, to continue with trastuzumab (6mg/kg body weight every three weeks) plus capecitabine (2,500mg/m2 on days 1-14, every 21 days) or to capecitabine alone.